We found no statistically significant difference, however, in the incidence of new organ failure or other complications between neostigmine and conventional treatment, although patients receiving neostigmine showed a trend toward less new-onset respiratory (2 of 40 vs. 6 of 40), renal (0 vs. 3) and overall organ (12 vs. 16) failure.
← all excerpts
Randomized controlled trial: neostigmine for intra-abdominal hypertension in acute pancreatitis.
1
—
—